Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-22T18:16:51.695Z Has data issue: false hasContentIssue false

Association of pro-inflammatory cytokines with PTSd severity in patients treated with omega-3 supplementation – a pilot study

Published online by Cambridge University Press:  23 March 2020

D. Kalinić*
Affiliation:
University of Zagreb School of Medicine, Department of Psychiatry and Psychological Medicine, Zagreb, Croatia
N. Mimica
Affiliation:
University of Zagreb School of Medicine, Department of Psychiatry and Psychological Medicine, Zagreb, Croatia
A. Jeroncic
Affiliation:
University of Split School of Medicine, Department of Research in Biomedicine and Health, Split, Croatia
M. Lalovac
Affiliation:
Clinical Hospital Merkur, Department of Internal Medicine, Zagreb, Croatia
I. Delaš
Affiliation:
University of Zagreb School of Medicine, Department of Chemistry and Biochemistry, Zagreb, Croatia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Association of pro-inflammatory cytokines with severity of various psychiatric disorders is shown. Evidence suggests omega-3 fatty acids reduce psychiatric symptoms due to anti-inflammatory properties.

Objectives

To evaluate if serum levels of pro-inflammatory cytokines correlate with the intensity of PTSD symptoms, and the observed change in symptoms’ severity induced by omega-3 supplementation.

Methods

We included 26 Croatian Homeland war veterans (aged 39–60) with chronic PTSD and no major comorbidity, who were on stable therapeutic sertraline dose at least three months before recruitment. Levels of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) were determined by the enzyme-linked immunosorbent assay method. Intensity of PTSD symptomatology was assessed by Clinician-Administered PTSD Scale (CAPS), Hamilton Anxiety Scale (HAM-A) and 17-item Hamilton Depression Scale (17-HAM-D). During 12 weeks, participants took omega-3 capsules (600 mg/day) while continuing sertraline therapy.

Results

Most participants presented with moderate PTSD evaluated by CAPS. At baseline, cytokine levels were not associated with the severity of PTSD symptoms, as measured by all three scales (P ≥ 0.209). After 12 weeks of omega-3 supplementation the severity of PTSD symptoms significantly decreased, on average by 8 to 13% on the psychometric scales per person (P < 0.001 for all). However, no association was found between the change in cytokine levels and the change in scores, induced by omega-3, on the assessed scales (P ≥ 0.730).

Summary

Cytokine levels are not associated with PTSD severity or with improvement in PTSD symptomatology. At the same time, sertraline therapy supplemented with omega-3 seemed to reduce the severity of PTSD symptoms.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW401
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.